MXCT Stock Price, Chart, Stats & News
MaxCyte, Inc. (MXCT) does not currently pay a dividend.
MXCT chart
Fundamentals
Gross margin | 68.36% |
Operating margin | -131.85% |
Pretax margin | -135.14% |
Net margin | -135.14% |
Effective tax rate | – |
ROA | -22.04% |
ROE | -24.06% |
D/E | 0.10x |
Interest coverage ratio | – |
MXCT valuation
P/E | – |
P/S | 2.21x |
P/B | 0.42x |
P/CF | -2.11x |
P/FCF | -2.02x |
P/OCF | -2.11x |
PEG | -0.72x |
EV multiple | -1.84x |
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
Similar securities
Based on sector and market capitalization
